PHIO

Phio Pharmaceuticals Corp. (PHIO) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics using its proprietary INTASYL self-delivering siRNA technology. The company operates as a single segment and has not yet recognized any product revenue. As of November 11, 2025, there were 10,764,428 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is $0 as the company is pre-commercial. Cash flow data for operating and financing activities is presented on a nine-month basis as per the filing.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses increased by 58% ($915k) in Q3 2025 compared to Q3 2024. This was driven by an 83% increase in R&D expenses (due to clinical trial and CMC costs for PH-762) and a 40% increase in G&A expenses (due to professional fees and stock-based compensation).
• Higher Net Loss: Net loss for Q3 2025 was $2.39 million, compared to $1.52 million in Q3 2024. On a nine-month basis, the loss increased to $6.33 million from $5.52 million.
• Significant Capital Raising: The company executed multiple financings in 2025, including registered direct offerings in January and a warrant inducement financing in July. Net proceeds from financing activities for the nine months ended September 30, 2025, were $11.2 million, compared to $2.6 million in the prior year period.
• Liquidity Improvement: Cash and cash equivalents grew from $5.38 million at year-end 2024 to $10.71 million at September 30, 2025.

Outlook, Risks, and Subsequent Events

• Subsequent Financing (November 2025): On November 3, 2025, the company entered into inducement agreements to exercise warrants for an aggregate of 5.66 million shares. Gross proceeds are approximately $13.4 million, with net proceeds expected to be approximately $12.1 million. This financing alleviates previous doubts regarding the company's ability to continue as a going concern.
• Clinical Progress: The Phase 1b trial for lead candidate PH-762 (targeting PD-1) continues. Pathologic results for the fifth cohort showed 100% tumor clearance in one patient, >90% in another, and >50% in the third. No dose-limiting toxicities were observed.
• Going Concern: Management believes current cash, including proceeds from the November 2025 financing, is sufficient to meet obligations for at least 12 months from the filing date.
• Risks: Key risks include the unproven nature of the INTASYL technology, potential delays in clinical trials, dependence on third-party manufacturers, and the need for substantial additional funding. The company also faces risks regarding compliance with Nasdaq listing requirements (minimum bid price).

Investor Verification Checklist

• Capital Runway: Verify the final net proceeds from the November 2025 financing and confirm the updated cash runway beyond the 12-month projection.
• Dilution Impact: Assess the dilution effect from the November 2025 warrant exercises and the issuance of new Series A warrants (11.3 million shares).
• Clinical Trial Enrollment: Monitor the pace of patient enrollment and data readouts for the PH-762 Phase 1b trial, specifically regarding the expansion cohorts.
• Nasdaq Compliance: Track the common stock price to ensure it remains above the $1.00 minimum bid price requirement to avoid delisting risks.
• PH-894 Status: Confirm the timeline for the deferred IND submission for the second candidate, PH-894, and any changes in resource allocation.